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Background: Few studies have focused on fatigue in myasthenia gravis (MG), and fatigue in relation to the
autonomic system has never been systematically explored in these patients. The study aimed to document the
prevalence of MG-related fatigue in ethnic Norwegians and to examine whether MG severity is associated with
symptoms of autonomic disturbance, which in turn is associated with fatigue and functional disability.
Methods: Eighty two of the 97 who fulfilled the study inclusion criteria participated in the study. Controls were
410 age- and sex-matched subjects drawn from a normative sample (n = 2136) representative of the Norwegian
population. Bivariate analyses and multivariate linear regression analyses were used to assess associations between
questionnaire-reported MG severity, symptoms of autonomic disturbance, fatigue (mental and physical) and
functional disability.
Results: Forty-four per cent (36/82) of patients fulfilled the criteria for fatigue compared with 22% (90/410) of
controls (odds ratio 2.0; p = 0.003). Twenty-one per cent of patients (17/82) met the criteria for chronic fatigue
versus 12% (48/410) of controls (odds ratio 1.96; p = 0.03). MG patients had higher total fatigue scores than controls
(p < 0.001) and a high prevalence of autonomic symptoms, especially poor thermoregulation and sleep disturbance.
According to multivariate analyses controlled for MG score, symptoms of autonomic disturbances were independently
positively associated with fatigue (p < 0.001), and fatigue was independently negatively associated with
functional level (p < 0.001).
Conclusion: Norwegian ethnic patients with MG have higher levels of fatigue and a higher prevalence of chronic
fatigue than controls, even in patients in full remission. MG severity is highly suggestive to be associated with
symptoms of autonomic disturbance, which in turn is associated with fatigue and the level of functional disability.
Keywords: Myasthenia gravis, Fatigue, Autonomic nervous system, Self report, Questionnaire, Acetylcholine
esterase inhibitorsBackground
Myasthenia gravis (MG) is a chronic autoimmune disease
that affects the neuromuscular junction, causing reduced
muscular strength and reduced endurance of repetitive
muscle use. Fatigue has been reported in both neurological
and non-neurological diseases, including MG, independent
of muscle weakness [1,2]. The perception of fatigue is
subjective and there is no consensus on an exact definition
[3]. Because fatigue is a complex phenomenon and
includes both physiological and psychological factors, a* Correspondence: ahmed.elsais@medisin.uio.no
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reproduction in any medium, provided the ordistinction has recently been made between fatigue as a
subjective feeling of tiredness, lack of energy, and difficulty
concentrating, and muscle fatigability defined as the
difficulty initiating or sustaining muscle activities [4].
Chronic fatigue is commonly defined as fatigue above a
certain level lasting for 6 months or more [5]. Persistent
fatigue of this type has been studied extensively in the
Chronic Fatigue Syndrome (CFS) and in some other
chronic diseases. In this study, the characteristics of
fatigue in CFS will be applied as a working definition of
chronic fatigue in MG patients.
Muscle fatigability has been mentioned in most MG
studies but only a few studies have investigated subjectivetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that MG patients have more fatigue than healthy controls
[7,8]; in one study 82% of MG patients complained of
fatigue and half of these also reported mental fatigue
which could only partly be explained by muscle fatigability
[7,8]. Another study found no direct association between
fatigue and neurophysiologically proven muscle fatigability
by use of decrement tests [8].
Using orthostatic stress and isometric muscle contraction
as challenges, previous studies of CFS found that feelings
of fatigue can be related to autonomic dysregulation [9,10]
Autonomic dysfunction as a result of deficient regulatory
mechanisms of the sympathetic nervous system in MG
patients has been reported [11-13]. Kimura and coworkers
suggested that cholinergic autonomic nerves may be
affected in MG patients even in the absence of clinical
signs of autonomic dysregulation [14]. Muscle and
neuronal acetylcholine receptors (AChR) are structurally
similar, and cross-immunity has been shown between
the two types of AChR antibodies in MG patients who
have the concomitant syndrome “autoimmune autonomic
neuropathy”. This syndrome responded to acetylcholine
esterase inhibitors (AChEI) [15], which could indicate
that presynaptic impairment is an underlying cause of
the autonomic disturbances in MG patients. However,
fatigue has never been studied in relation to autonomic
disturbances in MG patients.
We noted that MG patients often indicated a general
feeling of lack of energy and trouble concentrating, but
repeated clinical examinations showed no signs of mus-
cular weakness in many of these patients. These fatigue
symptoms did not improve after rest or the intake of
AChEI. This observation is the background for the present
study. Our primary goal was to test the hypothesis that
MG severity is associated with symptoms of autonomic
disturbance, and a secondary goal was to document the
prevalence of fatigue in myasthenia gravis patients.
Methods
Study sample
The patient registry of Oslo University Hospital, Riksho
spitalet, was used to identify ethnic Norwegian patients,
aged 19–74 years who were diagnosed with acquired
autoimmune MG between 1996 and 2006 (n = 125).
Diagnosis was based on conventional diagnostic criteria;
all patients had typical exertional muscle weakness, and
at least two supportive laboratory results, such as a
positive edrophonium test, and/or the presence of AChR
antibodies in serum, and/or neurophysiological findings
consistent with MG (decrement >10% at 3 Hz repetitive
motor nerve stimulation and/or increased jitter on
single-fibre electromyogram).
A detailed clinical neurological examination was per-
formed at least twice during the year before participationby two of the authors (AE, EK), including a muscle power
test of eye muscles (ptosis test and eye motility), bulbar
muscles (swallow and speech), muscle power in ex-
tremities, neck and respiratory muscles.
Clinical grading according to the Myasthenia Gravis
Foundation of America (MGFA) scale was performed on
the basis of the patient’s symptomatology and clinical
examination. Only patients with MGFA grade II or better
during the year prior to the start of the study, regardless
of the severity of their MG in the past, were invited to
participate (n = 97). The inclusion criteria for the present
study were a definitive MG diagnosis, clinical condition
not worse than MGFA grade II during the last year before
participation, and age between 19 and 74 years.
The statistical program SPSS 17.0 software (SPSS Inc.,
Chicago, IL, USA) was used to randomly draw five
age- and sex-matched controls per eligible patient from
normative data, representative of the Norwegian popula-
tion (n = 2136, age 19–74) [16]. Information about age,
body mass index (BMI), disease duration, comorbidities
and use of medication (especially AChEI) was obtained
from patient records. A questionnaire was sent to patients
and controls regarding sociodemographic status, fatigue
and duration of symptoms. MG patients also completed
two self-reported questionnaires on severity of MG and
symptoms of autonomic disturbance.
All study subjects signed informed consent forms. The
study was approved by the appropriate independent
hospital ethics committee.Questionnaires
Study subjects completed the Norwegian version of the
FQ (Fatigue Questionnaire) [16,17], which assessed fatigue
symptoms experienced during the past month compared
with the last time the subject felt well. Seven items related
to physical fatigue and four to mental fatigue. The FQ
also included a question about symptom duration. Each
of the 11 items had four response alternatives; “less
than usual” = 0; “same as usual” = 1; “more than usual” =
2; and “much more than usual” = 3, with a maximum
possible score of 33. The sum of responses to all items
was designated the “Total fatigue level” with a possible
range of scores between 0 and 33. The sum of responses
to the seven physical items indicated the level of “physical
fatigue” (score range 0–21). The sum of responses to the
four mental items indicated the level of “mental fatigue”
(score range 0–12).
Responses with alternatives were dichotomised; 0 and
1 = 0, 2 and 3 = 1. Substantial fatigue or “fatigue case-
ness” was defined as a sum score of dichotomised
responses ≥ 4 and chronic fatigue was defined as a sum
score of dichotomised responses ≥ 4 and symptom duration
of ≥ 6 months [16].
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25-item, disease-specific, patient-reported questionnaire
[18,19]. The authors used the validated Swedish version
[19], translating only a few terms into Norwegian (which
is very similar to Swedish). The global MGQ score was the
sum of scores for all items and ranged from 0 (maximal
impairment) to 50 (absence of any impairment). The score
of MGQ was validated as an outcome measure and was
found to correlate highly with clinical status and MG
severity [18,19].
The Autonomic Symptom Questionnaire is a validated
instrument for assessing symptoms of autonomic dys-
function [20]. The Autonomic Symptom profile (ASP)
used in the present study is a translation of an abridged
version (22 selected items) of the validated questionnaire,
and had been proven feasible in a previous study at our
institution [21]. The 22 items assessed orthostatic intoler-
ance, vasomotor function, sudomotor/thermoregulatory
function, gastroenterologic function, pupillary function
and sleep disturbance. The response alternatives were
partly dichotomous (“yes” and “no”), and were partly
scored from 1 to 5 on a Likert scale. In this study, the
responses to all ASP items were dichotomised and
assigned a value of 0 (symptom not/rarely present) or 1
(symptom often/always present). Autonomic symptom
scores were the sum across all ASP items and were in
the range 0–22. The ASP questionnaire also included
three items that addressed social and physical disability
on 1–5 Likert scales. The total disability score was the
sum of these three items in the range 3–15. There was an
Item assessing the symptoms of chronic fatigue syndrome
(CFS) [22], an item assessing the level of physical activity
during leisure time (total score range from 2–6), andFigure 1 Estimated analytical model. We assumed that every variable on
(i.e., variables at Level 4 could be explained by all variables at Levels 1 – 3). BMan item to cover comorbidity with possible autonomic
consequences either caused by the disease itself, hyper-
tension, heart disease, diabetes, thyroid abnormalities,
polyneuropathy, rheumatoid arthritis or their treatment.
Comorbidity was expressed as none = 0, one disease = 1,
and 2 or more = 2.
Statistical analysis
We constructed an analytical model including all plausible
factors as outlined in Figure 1. Based on theoretical
plausibility we assumed that variables could be grouped
into four “explanatory levels” and that each variable on
a lower level could be explained by variables on a higher
level in the hierarchy (e.g., variables at Level 4 could be
explained by all variables at Levels 1–3).
Variables contained within Level 1 were: age, sex, BMI,
physical activity during leisure, smoking, comorbidity,
disease duration, MGQ score, use of AChEI, and symptoms
related to chronic fatigue syndrome. Level 2 contained the
score of the ASP items, Level 3 contained the total fatigue
score, and Level 4 contained the functional (physical and
social) disability.
Data analysis was performed with SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA). The Student t-test or the
Mann–Whitney U test were used as appropriate to com-
pare the MG and control groups, and to compare fatigue
level between patients indicated to be symptomatic or
asymptomatic according to autonomic symptoms. Variables
that strongly deviated from normality were in-transformed
to obtain an approximate normal distribution. The po-
tential relationships between the variables within each
explanatory level were first explored using bivariate
linear regression analyses, and variables with p < 0.1 werea “lower” level could be explained by variables higher in the hierarchy
I = body mass index, AChEI = acetylcholine-esterase inhibitor.
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In each multivariate model, the distribution of residuals
was assessed for normality. For the multivariate regression
analyses, we report unstandardized regression coefficients
(Bs) with 95% confidence intervals (CIs). A p-value < 0.05
was considered statistically significant.Results
Eighty two of the 97 eligible MG patients completed the
questionnaires, a response rate of 85%. There were 32
men (mean age ± standard deviation (SD), 59 ± 14 years)
and 50 women (mean age, 50 ±16 years). The mean age of
all patients was 54 ± 16 years and mean disease duration
was 14 ±12 years. Fifty one patients had early onset
MG and 31 had late onset MG. Two patients had
thymoma-related MG and both underwent surgery with
a very good outcome. Mean BMI was 26.5 ± 5.7 kg/m2.
Of the 78 patients with AchR antibody data, 63 (81%)
were seropositive for AchR antibodies. Eight of the 15
AchR seronegative patients were tested against MuSK
(muscle specific tyrosine kinase), and all were negative.
All patients were MGFA grade II or better during the
year prior to the start of this study. Fifty patients (61%)
used an AChEI (pyridostigmine bromide) with maximum
dose 120 mg per day, and 39 patients (48%) used oral
steroids. Fifteen patients took azathioprine, two myco-
phenolate mofetil, one cyclosporine and one methotrexate.
Twenty one patients (26%) had no medication for at
least 6 months, either because of complete spontaneous
remission after thymectomy or because they had minimal
symptoms which did not need treatment. The controls
included 410 age- and sex-matched ethnic Norwegians,
160 men (mean age, 59 ± 14 years) and 250 women
(mean age, 50 ± 16).Fatigue prevalence
MG patients had higher total fatigue scores of 14.5 ± 5.5
compared with 12.4 ± 3.6 in controls (p = 0.001). Patients
also had higher physical fatigue scores of 9.8 ± 4.2
compared with 8.0 ± 3.0 in controls (p = 0.001). The
level of mental fatigue in patients was 4.7 ± 1.9 versus
4.5 ± 1.3 in controls (p = 0.03). Fatigue (total, physical
and mental) showed no significant difference between
males and females in the patient group.
Forty-four per cent (36/82) of patients fulfilled the criteria
for fatigue caseness (dichotomized score ≥ 4) versus
22% (90/410) in controls (odds ratio: 2.0; p = 0.003).
Chronic fatigue (dichotomized score ≥ 4 and symptoms
lasting 6 months or longer) occurred in 21% (17/82) of
patients compared with 11% (48/410) of controls (odds
ratio: 1.96; p = 0.03). Figure 2 illustrates the difference
in fatigue levels and the prevalence of fatigue caseness
and chronic fatigue among MG patients and controls.Bivariate and multivariate analysis
Of the explanatory variables in Level 1 (Figure 1), no
independent associations with fatigue level were found
for patients’ age, gender, BMI, disease duration, physical
activity or smoking. On the other hand, the MGQ score
and comorbidity showed a correlation with fatigue level.
A significant negative linear correlation was found
between the MGQ score and the ASP score, indicating
more autonomic symptoms among the patients most
severely affected by MG (Figure 3). The total fatigue
score was independently associated with comorbidity and
the scores for MG severity and ASP. The functional level
was associated with both the MG score and the total
fatigue score.
Prevalence of fatigue in relation to each
autonomic symptom
We stratified the patients into symptomatic and asymp-
tomatic groups according to each autonomic symptom.
We compared the prevalence of fatigue caseness and
the total fatigue score between symptomatic and asymp-
tomatic groups for each autonomic symptom. Symptom-
atic MG patients had significantly higher fatigue score
and prevalence of fatigue caseness for each autonomic
symptom, apart from gastrointestinal dysfunction. The
difference was especially highly significant for symptoms
of sleep disturbance and sudomotor/thermoregulation
dysfunction (p = 0.001) as shown in Table 1.
Discussion
The results confirmed our hypothesis that there is an
association between MG severity and symptoms of auto-
nomic disturbance, and these in turn are associated
with fatigue level and functional disability. Moreover,
the most important finding is that the fatigue levels in
MG patients, independent of their MG score, were
significantly associated with the scores of the autonomic
symptoms (p = 0.001). The strongest relationships were
found between fatigue and poor thermoregulation,
orthostatism and poor sleep. As expected, the frequency
and the level of fatigue was significantly higher in MG
patients compared with controls. A previous study of
28 MG patients reported subjective fatigue in 82%, and
half of these patients experienced cognitive as well as
physical fatigue [7]. Our study showed a prevalence of
fatigue caseness of 44%. However, our patients did not
have severe MG (MGFA 0-II) and elderly patients > 74
years were excluded to make the study comparable
with normative data. Furthermore, about 50% more
MG patients (21% vs 12%) reported chronic fatigue than
controls. The main strength of the present study is the
relatively large sample of both patients and controls,
and the standardized measure of fatigue caseness and
chronic fatigue.
Figure 2 Fatigue score and the prevalence of fatigue caseness and chronic fatigue among myasthenia gravis patients and controls.
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in clinical practice. Myasthenic muscle fatigability is a
central factor in MG diagnosis. A previous study showed
inconsistency between the subjective feeling of fatigue
and the MG-associated muscle fatigability proven by
neurophysiological tests such as repetitive nerve stimu-
lation [8]. Disease severity is the most important con-
tributory factor to fatigue in MG patients. However, we
found that even MG patients in complete stable remission
without detectable myasthenic weakness or medication
also reported significantly higher levels of fatigue than
controls suggesting that factors other than myasthenic
muscle weakness may be involved.Figure 3 Results of multivariate analysis. The results are presented as re
symptoms profile.Our study found no clear gender difference in the
frequency and level of fatigue in MG patients. In the
general Norwegian population, women had higher
fatigue levels than men [16]. The dominance of females
among MG patients could suggest that gender might
be a contributing factor to the high fatigue score, but
the bivariate analysis did not support this theory. One
study reported that MG patients had a higher BMI due
to steroid use, which could reduce their physical activity
and potentially be an explanation for fatigue [3]. In that
study, the mean ± SD patient BMI was much higher than
in our study 31.8 ± 6.8 vs 26.5 ± 5.7 kg/m2. We did not
find associations between BMI or physical restriction andgression coefficient B (95% confidence interval). ASP = autonomic
Table 1 Distribution of fatigue caseness and total fatigue levels among myasthenia gravis patients by type of
autonomic symptom and presence or absence of that symptom
Autonomic
symptom
All patients Fatigue cases Odds ratio
(95% CI)*
Total
fatigue level
p-values
(n = 82) (n = 36)
Sudomotor Symptomatic 26 17.0
(n = 41) 5.4 (2.1 – 14.0) 0.001**
Asymptomatic 10 12.0
(n = 41)
Sleep Symptomatic 22 16.8
disturbances (n = 38) 2.9 (1.2 – 7.3) 0.001**
Asymptomatic 14 12.5
(n = 44)
Orthostatism Symptomatic 20 16.1
(n = 36) 2.3 (1.0 – 5.7) 0.04**
Asymptomatic 16 13.3
(n = 46)
Vasomotor Symptomatic 15 16.5
(n = 26) 2.3 (0.9 – 5.9) 0.03**
Asymptomatic 21 13.6
(n = 56)
Gastrointestinal Symptomatic 9 16.3
(n = 18) 1.4 (0.5 – 4.0) ns
Asymptomatic 27 14.0
(n = 64)
* 95% Confidence interval for Odds ratio.
** The p-values were not adjusted for multiple testing.
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both fatigue and autonomic functions. We concluded
in a previous study that well-regulated MG patients
with fatigue showed an obstructive pattern in pulmonary
function tests and this was more pronounced in patients
using AChEI [23]. Sixty one per cent (50/82) of the MG
patients in our study used AChEI, which is suspected
to alter autonomic functions, but we did not find that
use of AChEI was an independent explanatory variable,
although patients using them had slightly higher total
fatigue scores than controls (mean ± SD: 15.0 ± 6.2 vs
13.8 ± 4.2). The influence of corticosteroids or immu-
nosuppressives did not reach statistical significance in
the bivariate analysis.
The difference in fatigue level was highly significant
between patients with symptoms related to thermoregula-
tory and sleep disturbances compared with those without
(Table 1). The frequency of sleep problems in our patients
was 46%. Comparable results were found in a newly
published study [24], which reported significant sleep
disturbance in 59% of 54 clinically stable MG patients.
Others reported reduced REM sleep in MG patients
with sleep disorders [25,26] and impaired memory in
MG patients with sleep apnoea [27].The correlation between fatigue and ASP scores
support previous reports which indicated an autonomic
disturbance in patients complaining of fatigue [9,10]. Poor
sleep quality and orthostatic intolerance have both been
reported in MG patients [11,28]. However, these findings
were not discussed in the context of fatigue in these pa-
tients. It is reasonable to address sleep disorders in MG as
it might be expected that they could aggravate fatigue.
There are some limitations in the present study. There
was no adjustment for depression, as there is an overlap
in symptomatology between depression and fatigue. The
cross-sectional design precluded a possible causal relation-
ship among variables. The impairment in muscle strength
in MG necessitates mental concentration for daily activities
which are normally done automatically. Therefore, it is
difficult to assess purely mental fatigue in MG patients.
An important limitation of this study is that the ASP
questionnaire has not been formally validated in the MG
population. However, this questionnaire provides a screen-
ing tool for patients with MG, and objective physiological
tests should be used in further studies. Some of the
symptoms assessed in this score may also be interrelated
with neuromuscular manifestations, such as pupillary
reactivity in the ASP that may overlap with diplopia in
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autonomic symptoms and fatigue, but are not proof of
causality. We applied the characteristics of fatigue in CFS
as a working definition for this study; however, it remains
an open question whether the mechanism behind the
fatigue is identical in these two separate conditions.
Our results can be used as a framework for further analysis.
The use of a self-report questionnaire may have contributed
in some degree to the extent of the relationships that
were observed.
Fatigue has been under-recognized in MG patients.
In the absence of a biomarker which could give an
objective evaluation of disease severity, patient assessment
was based on the patient’s perspective of their symptoms
and a clinical examination. Autonomic symptoms, espe-
cially thermoregulatory and sleep disorders and fatigue
should be taken more seriously than they usually are
in these patients. Fatigue could be misinterpreted as
myasthenic weakness and trigger a negative spiral, i.e.,
overmedication with AChEI, which in turn could ag-
gravate fatigue.
Conclusion
Our results indicate that fatigue is a considerable problem
in MG even in patients who are in full remission and
not taking medication. MG severity is highly suggestive
to be associated with symptoms of autonomic disturbance,
which in turn are associated with total fatigue level
and functional disability. Future research is needed to
understand the role and the mechanisms of autonomic
dysregulation in MG-related fatigue. New management
strategies should be explored to improve fatigue in
MG patients.
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